Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
about
T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment.(5R)-5-hydroxytriptolide (LLDT-8) prevents collagen-induced arthritis through OPG/RANK/RANKL signaling in a rat model of rheumatoid arthritisThe Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis.Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
P2860
Q39063866-9B050B44-851A-45CE-839C-60F546A089A8Q39157409-13CD83D6-6F5E-4BC0-B276-7E4A372AD5B9Q40068342-990F692A-2A8B-47AA-8D38-37BD64798B2DQ47439880-B1BF45C9-2814-4E16-A0CD-5191BAD4DEE4Q48556502-04282B6C-7BE6-49CD-B4D0-A7D7853D5101Q54125014-484C778C-3906-4FB6-94E9-4746FE8A3223Q54977224-D0B229BC-38B2-4065-ACAB-05B59D068A0A
P2860
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
description
2016 nî lūn-bûn
@nan
2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Efficacy and safety of tofacit ...... review of key Phase 2 studies
@ast
Efficacy and safety of tofacit ...... review of key Phase 2 studies
@en
Efficacy and safety of tofacit ...... review of key Phase 2 studies.
@nl
type
label
Efficacy and safety of tofacit ...... review of key Phase 2 studies
@ast
Efficacy and safety of tofacit ...... review of key Phase 2 studies
@en
Efficacy and safety of tofacit ...... review of key Phase 2 studies.
@nl
prefLabel
Efficacy and safety of tofacit ...... review of key Phase 2 studies
@ast
Efficacy and safety of tofacit ...... review of key Phase 2 studies
@en
Efficacy and safety of tofacit ...... review of key Phase 2 studies.
@nl
P2093
P2860
P921
P356
P1476
Efficacy and safety of tofacit ...... review of key Phase 2 studies
@en
P2093
Bethanie Wilkinson
David Gruben
Edward Keystone
Gene Wallenstein
Joel Kremer
Keith Kanik
Roy Fleischmann
Samuel H Zwillich
Sriram Krishnaswami
Tamas Koncz
P2860
P304
P356
10.1111/1756-185X.12901
P5008
P577
2016-07-25T00:00:00Z
2016-12-01T00:00:00Z